Imagine having a tiny, invisible pharmacy living on your skin. This project creates 'smart' bacteria that act like tiny sensors to detect when a skin flare-up is starting and automatically release medicine to stop it. It is like having a 24/7 security guard and doctor combined, living right in your skin's natural microbiome.
Current treatments for atopic dermatitis are often reactive and non-personalized. There is a lack of non-invasive tools that can both monitor skin health and deliver treatment simultaneously in real-time.
A genetic toolbox for C. acnes (including CRISPRi and surface display), computational models of skin microbiome interactions, and a high-throughput skin organoid platform.
If you are a biotech drug developer dealing with the difficulty of delivering precise doses for atopic dermatitis — this project developed engineered C. acnes that can detect skin signals and deliver therapeutics in real-time. This allows for personalized treatment that reacts to the patient's actual condition.
If you are a health-tech manufacturer dealing with the lack of biological data in wearables — this project developed sensing modules in bacteria that can be read by cameras or wearables. This enables at-home, on-demand skin health information for users.
If you are a skincare brand dealing with generic products that don't adapt to the user's microbiome — this project developed a genetic toolbox for C. acnes to create sensing and actuation circuits. This provides a path toward truly personalized, living skincare treatments.
Based on available project data, the specific cost per unit or implementation price is not provided, as the project is currently in the research and proof-of-concept phase.
The project is currently focusing on creating a high-throughput skin organoid platform for validation. Based on available project data, industrial scaling processes have not yet been established.
The project has developed a genetic toolbox for C. acnes including CRISPRi and genome integration platforms. Based on available project data, specific licensing terms are not yet disclosed.
The vision is to integrate these microbial devices with wearables and cameras to provide at-home monitoring and intervention for patients with atopic dermatitis.
The project period runs from 2023-02-01 to 2027-01-31, suggesting that commercial availability will follow the completion of these research milestones.
The consortium is heavily academic, consisting of 6 partners from 5 countries, with 5 universities and 1 research organization. There are 0 industry partners and 0 SMEs, indicating that the project is currently in a high-risk, high-reward discovery phase rather than a commercialization phase.
Contact the research office at Universidad Pompeu Fabra
Contact us to find a bridge between this academic research and your industrial pipeline.
